- Home
- CIO vs FHTX Comparison
CIO vs FHTX Comparison
Compare CIO & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIO
- FHTX
- Stock Information
- Founded
- CIO 2013
- FHTX 2015
- Country
- CIO Canada
- FHTX United States
- Employees
- CIO N/A
- FHTX N/A
- Industry
- CIO Real Estate Investment Trusts
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- CIO Real Estate
- FHTX Health Care
- Exchange
- CIO Nasdaq
- FHTX Nasdaq
- Market Cap
- CIO 280.5M
- FHTX 278.1M
- IPO Year
- CIO 2014
- FHTX 2020
- Fundamental
- Price
- CIO $7.01
- FHTX $4.64
- Analyst Decision
- CIO Hold
- FHTX Strong Buy
- Analyst Count
- CIO 1
- FHTX 5
- Target Price
- CIO N/A
- FHTX $11.80
- AVG Volume (30 Days)
- CIO 548.8K
- FHTX 132.3K
- Earning Date
- CIO 10-30-2025
- FHTX 11-03-2025
- Dividend Yield
- CIO 5.72%
- FHTX N/A
- EPS Growth
- CIO N/A
- FHTX N/A
- EPS
- CIO N/A
- FHTX N/A
- Revenue
- CIO $168,892,000.00
- FHTX $24,173,000.00
- Revenue This Year
- CIO $0.60
- FHTX $43.75
- Revenue Next Year
- CIO $3.53
- FHTX $1.27
- P/E Ratio
- CIO N/A
- FHTX N/A
- Revenue Growth
- CIO N/A
- FHTX N/A
- 52 Week Low
- CIO $4.19
- FHTX $2.95
- 52 Week High
- CIO $7.01
- FHTX $9.70
- Technical
- Relative Strength Index (RSI)
- CIO 74.58
- FHTX 41.69
- Support Level
- CIO $6.93
- FHTX $4.45
- Resistance Level
- CIO $6.97
- FHTX $5.12
- Average True Range (ATR)
- CIO 0.02
- FHTX 0.31
- MACD
- CIO -0.01
- FHTX -0.03
- Stochastic Oscillator
- CIO 93.75
- FHTX 25.68
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. Its properties includes: Pima Center, SanTan, Park Tower, Intellicenter, Intellicenter, Denver Tech, Canyon Park, AmberGlen and many. The company own these office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.